Fluorinated sEH Inhibitors for BBB Penetration and Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing soluble epoxide hydrolase (sEH) inhibitors lack sufficient metabolic stability, particularly against hepatic CYP-mediated metabolism, and are unable to effectively penetrate the blood-brain barrier (BBB), limiting their therapeutic potential for neurological diseases.
Innovation Solution
Development of new sEH inhibitors with high inhibitory activity and metabolic stability, including compounds of formula (I) that can cross the BBB, ensuring effective penetration into the CNS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing sEH inhibitors are used, then inhibitory activity is achieved, but metabolic stability against hepatic CYP-mediated metabolism is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of sEH inhibitors, specifically introducing fluorine atoms at positions 2 and 6 of the phenyl ring (formula I: R1=F, R2=F) and adjusting substituents at R3 and R4 positions. These structural parameter modifications enhance metabolic stability against CYP-mediated metabolism while maintaining high inhibitory activity, directly resolving the contradiction between reliability and stability.
Solution Approach 2:
The patent creates composite molecular structures combining the core sEH inhibitor scaffold with specific fluorinated phenyl groups and substituted piperidine or pyridine moieties. This composite approach integrates multiple functional elements: the core structure provides inhibitory activity while the fluorinated aromatic substituents confer metabolic stability, achieving both requirements simultaneously.
2Reliability
If existing sEH inhibitors are used, then inhibitory activity is achieved, but ability to penetrate blood-brain barrier is insufficient
Solution Approach 1:
The patent modifies molecular parameters including reducing overall molecular size, optimizing logP values through fluorine substitution (which increases lipophilicity), and adjusting the R3-R6 substituent patterns to enhance BBB permeability. These parameter changes enable effective CNS penetration while preserving high sEH inhibitory activity.
Solution Approach 2:
The patent applies local quality by introducing fluorine atoms at specific positions (R1 and R2 on the phenyl ring) and placing electron-withdrawing groups at R3-R6 positions. This localized modification strategy enhances BBB penetration at specific molecular regions while maintaining the overall inhibitory function, resolving the contradiction between activity and penetration capability.
3Ease of operation
If sEH inhibitors are developed for neurological diseases, then BBB penetration is required, but metabolic stability is compromised
Solution Approach 1:
The patent designs composite molecular structures where fluorinated phenyl groups (providing BBB penetration) are combined with metabolically stable core structures. The specific combination of R1=F, R2=F with substituted R3-R6 creates a synergistic effect where both BBB permeability and metabolic stability are achieved simultaneously, resolving the contradiction between penetration and stability for neurological disease applications.
Data Source
AI summary
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I)to processes for their obtention and to their therapeutic indications.